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ABSTRACT
The Schizosaccharomyces pombe rad31 and hus5
genes are required for the DNA damage response, as
mutants defective in these genes are sensitive to
DNA damaging agents, such as UV and ionising radi-
ation and to the DNA synthesis inhibitor hydroxyurea
(HU). Sequence analysis has suggested that rad31
and hus5 encode components of the Pmt3 (SUMO)
modification process in S.pombe. We show here that
the rad31 null and hus5.62 mutants display reduced
levels of Pmt3 modification. We have initiated a
search for proteins required for the DNA damage
response, which may be modified by Pmt3 and have
identified Rad22, the fission yeast homologue of the
recombination protein Rad52. Purification of myc +
His-tagged Rad22 protein from cells expressing
HA-tagged Pmt3 identifies an 83 kDa species which
cross-reacts with anti-HA antisera. We show here
that Rad22 interacts with Rhp51 and Rpa70 (the
fission yeast homologues of Rad51 and the large
subunit of RPA, respectively), but that neither of
these proteins appears to be responsible for the
83 kDa species. The 83 kDa species is observed
when extracts are prepared under both native and
denaturing conditions, and is also observed when
myc + His-tagged Rad22 and Pmt3 are expressed at
wild type levels, suggesting that Rad22 is modified
by Pmt3 in vivo. We have established an S.pombe
in vitro Pmt3 modification system and have shown
that Rad22 and Rhp51 are modified in vitro, but that
Rpa70 is not.
INTRODUCTION
The DNA damage response involves the coordination of a
number of processes including DNA repair events and check-
point arrest mechanisms. Defective DNA damage responses
are identified as sensitivities to DNA damaging agents, such as
UV and ionising radiation, or to the DNA synthesis inhibitor,
hydroxyurea (HU). In mammalian cells, defects in the DNA
damage response can lead to cancer or chromosome abnormal-
ities. The fission yeast, Schizosaccharomyces pombe, has
proved to be a good model for the characterisation of DNA
damage response processes as analysis of mutants sensitive to
radiation and to HU has identified many genes required either
for repair of DNA damage or for the DNA integrity check-
points, which are conserved between S.pombe and mammals
(1,2). Among the S.pombe DNA damage response mutants are
two, hus5 and rad31, which are epistatic to each other and
which do not clearly define a repair process (3,4). Double
mutant analysis indicates that the genes function in a process
that also requires genes involved in the DNA integrity check-
point, but they are not actually required for the activation of the
checkpoint. The hus5.62 allele and the rad31 null mutant
display morphological abnormalities including aberrant cell
and nuclear morphology, sensitivity to UV and ionising radi-
ation and a high rate of loss of mini-chromosomes (3,4).
Comparison of the sequences of the rad31 and hus5 genes (3–5)
with sequence databases suggests that rad31 and hus5 encode
components of the fission yeast SUMO modification system.
SUMO is a small ubiquitin-like modifier of ∼100 amino
acids (reviewed in 6). It has been found complexed to a range
of proteins, most of which are associated with the nucleus,
e.g. PML, p53, IκBα (e.g. 7–12). The role of SUMO modifica-
tion has not been fully identified, but is likely to include roles
in facilitating protein–protein interactions and alterations in the
nuclear localisation of proteins (e.g. 7,13). In the fission yeast,
S.pombe, SUMO is encoded by the pmt3 gene. Deletion of
pmt3 results in a pleiotropic phenotype (14) similar to that
observed in the rad31 null and hus5.62 strains, consistent with
multiple roles for SUMO modification.
SUMO modification of proteins requires initial processing
of precursor SUMO to the mature form to reveal a GG motif
necessary for conjugation to target proteins (e.g. 15). Mature
SUMO is then activated by attachment to a protein
heterodimer (described below), before transfer to a conjugator
protein, which in turn is responsible for attachment of SUMO
to target proteins (reviewed in 6). In Saccharomyces cerevisiae
the activator is encoded by AOS1 and UBA2 (16), while the
conjugator is encoded by UBC9 (5). In fission yeast, sequence
comparisons indicate that the likely homologues to the acti-
vator genes are rad31 (4) and fub2 (14), while the conjugator is
encoded by hus5 (3) (see Fig. 1A). In support of this, the
S.cerevisiae AOS1 gene, which has a high degree of sequence
similarity to rad31 (16), complements the rad31 null pheno-
type (4).
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Two highly conserved recombination proteins, Rad51 and
Rad52, interact with either SUMO-1 (one of the mammalian
SUMO proteins) or components of the SUMO-1 modification
machinery. Using the yeast two-hybrid system, mammalian
Rad51 was demonstrated to interact with SUMO-1 (17). In
separate screens, the mammalian Rad51 and Rad52 proteins
were found to interact with Ubc9, the S.cerevisiae Smt3 conju-
gator (18,19). More recently both Rad51 and Rad52 have been
shown to co-immunoprecipitate with SUMO-1 and UBC9
(20). Conjugation of SUMO-1 to either of these proteins was
not detected.
Rad51 and Rad52 have major roles in genetic recombination
and in the repair of double strand DNA breaks. The mammalian
and budding yeast Rad51 and Rad52 proteins have been
purified and their activities characterised. Rad51 is a structural
and functional homologue of RecA and is required for DNA
strand exchange (21). In vitro studies suggest that Rad52,
along with RPA, promotes the strand exchange activity of
Rad51 (22). Rad52 has been shown to function as a heptameric
ring (23) and to bind resected DNA ends (24). The fission yeast
homologues of the rad51 and rad52 genes have been cloned
[the rhp51 and rad22 genes, respectively (25–27)], but little is
known about the activities or interactions of the gene products.
Deletion of either gene results in a high degree of sensitivity to
both UV and ionising radiation and in the case of the rhp51
null allele, a slow growth phenotype, indicating major roles in
normal cell growth as well as in the repair of damage due to
exposure to DNA damaging agents.
In this report we first confirm that rad31 and hus5 are
required for Pmt3 modification in S.pombe. We also describe
some results of a search for DNA damage response proteins
likely to be modified by Pmt3, the fission yeast homologue of
SUMO-1. One of the proteins we have identified is Rad22. We
have analysed the interactions between Rad22 and Pmt3, as
well as between Rad22 and other DNA metabolism proteins,
specifically Rhp51 (the S.pombe homologue of Rad51) and
Rpa70, the large subunit of RPA. To facilitate the investigation
into whether Rad22 is modified by Pmt3 we have established
an in vitro SUMO modification system from S.pombe protein
components and used this to determine whether Rad22 or the
proteins with which it interacts are modified by Pmt3.
MATERIALS AND METHODS
Strains and plasmids
The S.pombe strains used in this study were sp.011 (ade6.704,
ura4.D18, leu1.32, h–), sp.333 (rad31::ura4, ade6.704,
leu1.32, ura4.D18, h–), sp.376 (hus5.62, ade6.704, leu1.32,
ura4.D18, h+), sp.424 [rad22::ura4, leu1.32, ade6.704 h+ (26)]
and sp.568 (int mycHis-rad22/pSTA18, ade6.704, ura4.D18,
leu1.32, h–). sp.568 was created by first amplifying the rad22
coding sequence by PCR from genomic DNA using the
following primers: 5′-AAGCTAGAACATATGTCTTTT-
GAGCAA and 5′-TTTGCCTGGATCCTTTTATCCTTTTTT-
GG. The rad22 coding sequence was checked for ability to
complement the rad22 disruption strain (26). The 5′ upstream
region of the rad22 gene was amplified using primers 5′-AAG-
TATGGACCATGGGCTT and 5′-CAAAAGACATATGT-
TCTAGCT, and cloned upstream of the rad22 coding
sequence. A 100 bp NdeI fragment containing 2× myc + 6× His
(28) was inserted between the promoter fragment and the
rad22 coding sequence. The promoter-containing tagged
rad22 sequence was then subcloned into the integrating vector
pSTA18 (29) and used to transform S.pombe sp.011 cells to
adenine prototrophy. The integrated tagged rad22 strain was
analysed to ensure that there was no phenotype such as altered
cell or nuclear morphology, rate of cell growth or cell viability,
or alterations in the DNA damage response, due to the
presence of the myc + His tag. For expression studies in
Escherichia coli the rad22 ORF was subcloned into pET15b
(Novagen). The full-length pmt3 coding sequence was ampli-
fied by PCR using the following primers: SEN4, CTGTGAA-
CATATGTCTCATG; and Pmt3-4, TGGAGAGGATC-
CACGTATTGG. The rhp51 coding sequence was amplified
by PCR using the following primers: r51a, TAACAAGTTAC-
CATGGCAGATA; and r51b, TAGGATCCTTTAGACAG-
GTGCGAT, and checked for function by its ability to comple-
ment the rhp51 null mutation. The rpa70 coding sequence was
a gift from A. M. Carr (Sussex) (30). The rad22, rhp51 and
rpa70 ORFs were all amplified as NdeI–BamHI fragments to
allow subsequent cloning into the appropriate expression vectors.
The PML wild type and mutant ORFs cloned into pSG5 were
gifts from F. Lehembre (8,9). The S.pombe expression vectors
used were pREP41 (31), pREP41HA and pREP42MH (28);
pREP41HA and pREP42MH contain a haemagglutinin tag and
2× myc + 6× His tags, respectively, and were used to produce
in-frame protein fusions by insertion of coding sequences
between the Nde1 and BamHI sites of the two vectors.
Protein extraction and immunological methods
Whole cell TCA extracts were prepared as described by
Caspari et al. (32). Ni2+ affinity chromatography was under-
taken under either non-denaturing or denaturing conditions.
The non-denaturing conditions were those described by
Novagen with the inclusion of N-ethylmaleimide (10 mM),
iodoacetamide (10 mM), NaF (50 mM), NaN3 (10 mM) and
mammalian protease inhibitor cocktail (Sigma) (0.2%). Ni2+
affinity purification under denaturing conditions was carried
out as follows: cells were lysed into buffer A (6 M guanidine–
HCl, 0.1 M NaPO4 buffer, 0.01 M Tris pH 8.0, 5 mM imidazole,
10 mM β-mercaptoethanol) and insoluble material removed by
centrifugation. The supernatant was incubated with Ni2+
agarose for 2 h at room temperature. The Ni2+ agarose was then
washed in buffer A, followed by buffer B (as buffer A with
8 M urea instead of guanidine–HCl), then in Novagen wash
buffer plus 6 M urea, 20 mM imidazole and protein was eluted
in 6 M urea, 300 mM imidazole.
The Rad22–Hus5 interaction was investigated by mixing
two bacterial cell lysates of 50 ml cultures expressing
His-Rad22 (from pET15b) and GST-Hus5 (from pGEX) and
purification of the GST-Hus5 protein using glutathione–
Sepharose beads (Pharmacia) as described by the manufac-
turers, followed by SDS–PAGE.
Anti-Pmt3 antisera were produced using a His-tagged fusion
protein of an N-terminally truncated version of Pmt3
(N∆Pmt3) created by PCR using oligonucleotides Pmt3-1
(CTGAGAACATATGTCTGAATCACC) and Pmt3-4. Anti-
ubiquitin antisera were obtained from DAKO, anti-myc
antisera were from RDI Inc., anti-HA antisera were from
Babco and anti-His antisera were from Pharmacia.
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In vitro SUMO-1 modification assay
Amplification of the rad31 cDNA has been described previously
(4). The fub2 ORF was amplified by PCR using the following
oligonucleotide primers: Uba2p-N, CATATGCCAAG-
GCTAATGCAAC; and Uba2p-B, GGATCCAAATGGTT-
TATTTACATAG. The hus5 ORF was a gift from A. M. Carr
(Sussex). The ORFs were cloned into pGEX and Rad31, Fub2
and Hus5 proteins were purified as GST fusion proteins from
E.coli. The GST was cleaved off the GST–Hus5 fusion using
thrombin (5 U/mg protein) and Hus5 was purified by passage
over glutathione–Sepharose. Pmt3-GG, a C-terminally truncated
version of Pmt3 equivalent to the mature form was produced
with an N-terminal His tag and was constructed by PCR using
oligonucleotides SEN4 and Sumo-GG (GGATCCTAAG-
GAGGTAACTGTTCT). Radio-labelled proteins were
produced with [35S]methionine using the TnT T7 coupled
reticulocyte lysate system (Promega). The in vitro Pmt3 modi-
fication assay was carried out in 50 mM Tris–HCl pH 7.5,
5 mM MgCl2, 5 mM ATP, 10 mM creatine phosphate, 3.5 U/ml
creatine kinase, 0.6 U/ml inorganic pyrophosphatase using 3 µg
Hus5, 10 µg His-Pmt3, 0.5 µg SAE1 (GST–Rad31 + GST–Fub2)
and 2 µl 35S-labelled protein from the TnT reaction at 30°C for
2 h. Reactions were analysed by SDS–PAGE followed by
analysis on a phosphorimager.
RESULTS
Pmt3 modification of S.pombe proteins
Sequence comparisons suggest that rad31 and hus5 encode
components of the S.pombe Pmt3 (SUMO) modification
process. To confirm that the Rad31 and Hus5 proteins are actually
required for Pmt3 modification, we first wished to investigate
the levels of Pmt3-conjugates in the rad31 null and hus5.62
mutant strains. Anti-Pmt3 antisera were prepared as described
in the Materials and Methods. Figure 1B shows that they are
specific for Pmt3 and do not cross-react with ubiquitin. We
next compared the pattern of Pmt3-modified species in wild
type, rad31 null and hus5.62 mutant cells. Analysis of rad31
and hus5 mutant cells indicates a decrease in modified species
in both rad31 null and hus5.62 strains with a concomitant
increase in free Pmt3 (Fig. 1C), confirming that rad31 and
hus5 have roles in Pmt3 conjugation. The low residual level of
Pmt3-conjugates in the rad31 null mutant most likely results
from the activity of Fub2 which contains the conserved
cysteine residue that forms a thiolester bond with Pmt3. Deletion
of rad31 may not, therefore, completely abolish the activity of
Fub2. In the case of hus5.62, this allele has previously been
shown to be a partial loss-of-function mutation (3) and
presumably allows a low level of Pmt3 conjugation.
We next wished to determine whether exposure of cells to
ionising radiation or HU affected the overall pattern of Pmt3-
conjugates in wild type cells. We therefore subjected cells to
ionising radiation (500 Gy) or HU (20 mM for 3 h), prior to
protein extraction and western analysis. We did not detect any
major differences after exposure to any of the conditions that
we tested (data not shown). We also tested whether over-
expression of Pmt3 in S.pombe cells affected the resistance of
cells to UV or ionising radiation [as over-expression of SUMO-1
has been shown to result in a decrease in the resistance of
mammalian cells to ionising radiation (20)]. Cells over-
expressing either tagged or untagged Pmt3, using pREP41HA
and pREP41, respectively, or an untagged truncated version of
Pmt3 (Pmt3-GG), using pREP41, displayed similar sensitiv-
ities to UV and ionising radiation as wild type cells trans-
formed with empty vector (data not shown).
Search for Pmt3-associated proteins identifies Rad22 as a
likely candidate
The fact that the rad31 and hus5 mutants are sensitive to UV,
ionising radiation and HU suggests that Pmt3 modification is
required for some aspect(s) of the DNA damage response. We
therefore sought to identify Pmt3-modified targets likely to
have a role in the DNA damage response. We screened a
number of DNA damage response proteins for interaction with
Pmt3 by over-expressing them as myc + His-tagged fusion
proteins in cells also over-expressing HA-tagged Pmt3,
followed by affinity purification on Ni2+ agarose. The charac-
terisation of some of these genes will be described elsewhere.
One of the proteins we investigated in more detail was Rad22,
the S.pombe homologue of Rad52. Figure 2A (lane 3) shows
that indeed Rad22 and Pmt3 interact as a new HA-tagged
(i.e. Pmt3-modified) 83 kDa species is detected when both
proteins are over-expressed. This species is not detected when
either HA-Pmt3 (lane 1) or myc + His-Rad22 (lane 2) are
expressed on their own. The presence of two bands in lanes 2
and 3 after blotting with anti-myc antisera is likely to be due to
proteolysis as only a single species, corresponding to the upper
Figure 1. Pmt3 modification in S.pombe. (A) Schematic showing the components
of the S.cerevisiae and S.pombe Pmt3 modification pathway. The S.cerevisiae
nomenclature is taken from previous studies (5,16). (B) Anti-Pmt3 antisera are
specific for Pmt3 and do not recognise ubiquitin. N∆Pmt3 (lanes 1 and 3) and
ubiquitin (0.5 µg) (lanes 2 and 4) were separated by SDS–PAGE (12.5%) and
western blotted with anti-Pmt3 antisera (lanes 1 and 2) or anti-ubiquitin antisera
(lanes 3 and 4). (C) SDS–PAGE and western blotting with anti-Pmt3 antisera
of protein extracts from wild type (sp.011) lane 1, rad31.d (sp.333) lane 2 and
hus5.62 (sp.376) lane 3.
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band is observed in the TCA extracts (lanes 6 and 7). The size
of the species observed in lane 3 (∼83 kDa) is consistent with
that expected of an HA-Pmt3-modified form of myc + His-
Rad22.
No gross differences in Pmt3-modified species are observed
in whole cell TCA extracts of wild type and rad22 null cells
(Fig. 2A, lanes 4 and 5), indicating that the 83 kDa species is
not one of the major Pmt3-modified species in S.pombe.
It is possible that the 83 kDa species observed in Figure 2A
might be an HA-Pmt3-modified form of a protein that interacts
with Rad22, rather than Pmt3-modified Rad22. To determine
whether this might be the case, we investigated whether Rad22
interacted with two possible candidates, Rhp51 and Rpa70.
Rhp51 and Rpa70 are the homologues of Rad51 and the large
subunit of the single strand DNA binding protein (RPA)
which, in other organisms, have been shown to interact with
Rad52, the homologue of Rad22 (33,34). Myc + His-tagged
Rad22 was, therefore, over-expressed along with either
HA-tagged Rhp51 or HA-tagged Rpa70. Figure 2B (lane 2)
shows that Rad22 interacts with Rhp51 as observed by the
∼60 kDa species present in lane 2, but which is not present in
the negative controls (lanes 1 and 3). Similarly, Rad22 interacts
with Rpa70 (Fig. 2C, lane 2) with a species of ∼72 kDa pulled
down specifically with myc + His-tagged Rad22, and which is
not observed in the absence of HA-Rpa70 (lane 1) or myc +
His-Rad22 (lane 3). The sizes of the HA-tagged species
detected in Figure 2B and C are as expected for tagged, but
unmodified, forms of Rhp51 and Rpa70 proteins, respectively,
and are distinctly smaller than the 83 kDa Pmt3-associated
species identified in Figure 2A, as they migrate at 60 and
72 kDa, respectively. These data suggest that although Rad22
interacts with both Rhp51 and Rpa70, neither of these proteins
is likely to be a candidate for an 83 kDa Pmt3-modified Rad22-
interacting protein.
Figure 2. Interaction of Rad22 with Pmt3, Rhp51 and Rpa70. (A) Interaction with Pmt3. (B) Interaction with Rhp51. (C) Interaction with Rpa70. In all cases wild
type cells (sp.011) were transformed with plasmids expressing the indicated proteins as tagged fusion proteins under the control of the nmt1 promoter. Protein
interactions were investigated using Ni2+ agarose beads, TCA extracts were used as controls to check expression levels. Samples were analysed by SDS–PAGE and
western blotted with anti-myc or anti-HA antisera as indicated. *, New HA-cross-reacting species.
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Further analysis of the interaction between Rad22 and
components of the Pmt3 modification process
As analysis of the interactions of Rad22 with Rhp51 and
Rpa70 suggests that neither Rhp51 nor Rpa70 appears to be
responsible for the 83 kDa species detected in Figure 2A, we
wished to further analyse the relationship between Rad22 and
Pmt3 and with components of the Pmt3 modification process.
We first investigated whether Rad22 interacts with the Pmt3
conjugator, Hus5. This was analysed in vitro using GST-Hus5
and His-tagged Rad22. Figure 3A shows that GST-Hus5 interacts
with Rad22 protein in vitro, as Rad22 is pulled down with
GST-Hus5 using glutathione–Sepharose (lane 2), but not in the
absence of Hus5 (lanes 1 and 2). The relative amount of Rad22
which purifies with Hus5 (lane 2) and which remains in the
supernatant is low (lane 8), suggesting that the interaction
between Rad22 and Hus5 is transient in nature.
To further investigate whether Rad22 is modified by Pmt3,
we wished to establish whether HA-Pmt3 is associated with
Rad22 under denaturing conditions. The Ni2+ pull down assay
described in Figure 2A was, therefore, repeated in the presence
of guanidine–HCl which would be expected to disrupt non-
covalent interactions. Figure 3B shows that the 83 kDa species
is still pulled down with the myc + His-Rad22 protein (lane 2),
but not when Rad22 or Pmt3 are over-expressed alone (lanes 1
and 3), implying that Rad22 is modified by HA-Pmt3.
The interactions observed so far between Rad22 and Pmt3 or
Hus5 have been either under conditions where Rad22 and
Pmt3 are over-expressed, or in vitro. To confirm that the
83 kDa species we observe in Figures 2A and 3B is not an
artefact due to over-expression of either Rad22 or Pmt3, we
created an S.pombe strain containing an integrated myc +
His-tagged copy of rad22, repeated the Ni2+ pull down assay
and probed with anti-Pmt3 antisera. Figure 3C shows that the
83 kDa species is observed in cells expressing wild type levels
of both Rad22 and Pmt3 (lane 5), but not in the control sample
(lane 6). The level of the 83 kDa species is low in comparison
Figure 3. Interaction of Rad22 with Hus5 and Pmt3. (A) Bacterial cell lysates were mixed as indicated and proteins were fractionated on glutathione–Sepharose.
Proteins binding to glutathione (GST-pull down), crude extract and unbound material (supernatant) were separated by SDS–PAGE and western blotted with anti-His
antisera or stained with Coomassie Brilliant Blue. (B) Interaction of Rad22 and Pmt3 was analysed using extracts from cells over-expressing both proteins as in
Figure 2A, but in the presence of 6 M guanidine–HCl. (C) Interaction of Rad22 and Pmt3 expressed at wild type levels. Strains used were an integrated myc + His-tagged
Rad22 strain (sp.568) and sp.011 as the negative control. Samples were analysed by SDS–PAGE and western blotted with anti-myc or anti-Pmt3 antisera as
indicated. Lanes 1–4, 7 and 8 were exposed to X-ray film for 10 s, while lanes 5 and 6 were exposed for 30 min.
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to the amount of myc + His-tagged Rad22 pulled down in this
experiment (note the different exposure times of lanes 5 and 6
compared with that of the other lanes). The bands observed in
lane 5 were visible at the exposure time used for lanes 1–4, but
were faint. In addition to the 83 kDa species, an additional
species at ∼110 kDa is also observed. The identity of this is
unknown, but its size is consistent with it being Rad22-modified
by two Pmt3 molecules. Our inability to detect the 83 kDa
species in anti-myc blots may reflect masking of the myc
epitope by the Pmt3 modification of the different affinities of
the anti-myc and anti-HA antisera.
Rad22 is SUMO-1-modified in vitro
The results of the analysis of Rad22 in vivo are strongly
suggestive that Rad22 is modified by Pmt3. However, as Pmt3
modification is difficult to observe in cells because the modifi-
cation appears to be labile and Pmt3-modified species are
present at a low level, we wished to use a further method for
analysing Pmt3 modification of proteins. We therefore
established an in vitro Pmt3 modification system using
S.pombe components (as described in the Materials and
Methods). Figure 4A shows the protein components that were
purified for use in the assay. By analogy with the S.cerevisiae
Figure 4. Schizosaccharomyces pombe in vitro Pmt3 modification system. (A) Protein components used to establish the assay. Coomassie stain of SDS–PAGE.
Lane 1, 4 µg Hus5; lane 2, 10 µg His-Pmt3-GG; lane 3, 1 µg GST-Rad31, GST-Fub2. (B) Modification of PML. Assays were set up as described in the Materials
and Methods; all samples were incubated in assay buffer for 2 h at 30°C. Lanes 1–7, wild type PML; lanes 8 and 9, PML-3K-R. Lanes 1 and 2, all assay components; lane
3, no Hus5; lane 4, no Pmt3; lane 5, no Rad31 + Fub2; lane 6, no added ATP; lanes 7 and 9, no Hus5, Pmt3, Rad31 and Fub2. (C–E) Testing for modification of
Rad22 (C), Rhp51 (D) and Rpa70 (E). Addition of components was as indicated. (C) *, Major Pmt3-modified product; <, minor Pmt3-modified species of 105 kDa.
Nucleic Acids Research, 2001, Vol. 29, No. 20 4185
and mammalian homologues it was presumed that Pmt3 needs
to be processed to reveal the GG motif for conjugation onto
target proteins. Thus, for the in vitro system we prepared
His-tagged Pmt3-GG as described in the Materials and
Methods (Fig. 4, lane 2). Several procedures were tested for
the preparation of the activator (Rad31 + Fub2) and the
conjugator (Hus5) with the result that we obtained maximum
yields of soluble protein by preparing the three proteins as GST
fusion proteins. Rad31- and Fub2-containing E.coli extracts
were mixed together prior to purification on glutathione–
Sepharose as this prevented precipitation of the individual
proteins. The GST moiety was removed from Hus5, but not
from Rad31 and Fub2.
The S.pombe in vitro Pmt3 modification system was first
tested using the well established mammalian SUMO-1 target
protein, PML. Figure 4B shows that the system is capable of
modifying wild type PML protein (lanes 1 and 2), but not an
unmodifiable version of it (lane 8). The modification is
dependent on the presence of Rad31, Fub2 and Hus5 as omis-
sion of any one of these components results in loss of the
modification (lanes 3–5, 7 and 9). Omission of added ATP did
not prevent the reaction. This appears to be in contrast to what
has been observed in the mammalian in vitro SUMO-1 modifi-
cation system (12), but is likely to be due to the presence of
ATP in the reticulocyte lysate used here to create labelled
substrates.
We next investigated whether Rad22 was modified in this
in vitro system. Figure 4C (lane 1) indicates that Rad22 is
indeed modified in vitro. The size of the major modified
species corresponds well with the size of the Pmt3-associated
species observed in vivo (e.g. Fig. 3C). (The species detected
in vivo would be expected to migrate slightly slower than the
forms detected in vitro as the Rad22 species expressed in yeast
contains two additional myc epitopes.) There is also a very
minor species at 105 kDa which migrates with similar relative
molecular mass to the larger species observed in Figure 3C,
lane 5. As with PML, the modification of Rad22 is dependent
on the presence of added SAE (Rad31 + Fub2), Hus5 and Pmt3
(lanes 2–4).
We also investigated whether proteins which interact with
Rad22 are modified by Pmt3 in vitro. Figure 4D, lanes 1 and 2,
shows that Rhp51 is modified by Pmt3 in vitro, while Rpa70
does not appear to be (Fig. 4E, lanes 1 and 2). Modification of
Rhp51 is dependent on the presence of added Hus5 and SAE
(Rad31 + Fub2) (Fig. 4D, lanes 3–5).
DISCUSSION
We have confirmed here our speculation, derived from
sequence comparisons, that the rad31 and hus5 genes encode
components of the S.pombe SUMO-1 (Pmt3) conjugation
machinery. The S.pombe in vitro Pmt3 modification system,
which we describe and which uses purified Rad31, Fub2 and
Hus5 enzymes, is capable of modifying the mammalian protein
PML, but not a mutant version of it that has been shown in the
mammalian SUMO-1 modification system to be unmodifiable
(8). The levels of Pmt3 modification in the S.pombe system,
while low, resemble the levels of SUMO-1 modification
observed using the mammalian system (e.g. 12). The Pmt3
modification that we detect requires the presence of added
Pmt3-GG (the mature form of Pmt3), the activator (Rad31 +
Fub2) and the conjugator, Hus5. As with the mammalian
in vitro SUMO-1 modification system, the S.pombe system
does not appear to require a Pmt3 ligase, although it is possible
that such an activity might be contributed by the rabbit reticu-
locyte lysate system used to prepare 35S-labelled substrates.
We have obtained similar results using substrates labelled in
the TnT wheatgerm system (data not shown), indicating that if
a Pmt3 ligase is required it is also being provided by the wheat-
germ extract. A Pmt3 ligase is unlikely to have co-purified
with any of the modification components, as they were all
prepared from E.coli, which does not have ubiquitin or ubiquitin-
like proteins.
The UV, ionising radiation and HU sensitivities of the rad31
null and hus5.62 mutants imply that Pmt3 modification has a
role in one or more aspects of the DNA damage response.
Previous work on SUMO-1 has shown that the majority of
SUMO-1-modified proteins are located within the nucleus
(35), although there are exceptions to this (e.g. 36). The range
of defects observed in rad31, hus5 and pmt3 mutant strains
(3,4,14) suggest that there are likely to be several, or possibly
many, proteins involved in aspects of DNA metabolism or the
DNA damage response which have their function modulated
by Pmt3 modification. Among a number of DNA damage
response proteins we have tested, we identified Rad22 as a
potential Pmt3-modified target. Taken together, the data
described here, in particular the interaction of Rad22 and Pmt3
under denaturing conditions (Fig. 3B) and when both proteins
are expressed at wild type levels (Fig. 3C), strongly suggest
that Rad22 is modified by Pmt3. From these experiments we
estimate that the level of the modified species is ∼2–5% of the
level of the unmodified Rad22 protein. The presence of two
Pmt3-modified species observed in Figure 3C may indicate
that Rad22 is modified by two Pmt3 molecules. The majority
of the cases of multiple sumoylation have been shown to be
due to single SUMO-1 molecules attached to multiple sites.
However, there is a recent report of SUMO-2 and SUMO-3
forming polymeric chains (37). Whether Pmt3 is able to form
chains remains to be determined.
In addition to Rad22, the in vitro Pmt3 modification system
is also capable of modifying Rhp51. However, in contrast to
what we observe with Rad22 in vivo, we have not detected any
species which might correspond to Pmt3-modified Rhp51
when, for example, we over-express myc + His-Rhp51 and
HA-Pmt3 under similar conditions to those described in Figure 2.
The reason for this is not known but may be due to the presence
of very low levels of Pmt3-modified Rhp51 or that Pmt3-
modified Rhp51 is highly unstable in vivo. The fact that we do
not detect modification of Rpa70 indicates that not all
substrates tested in the in vitro system give positive results.
During these and other in vivo studies that we have undertaken
to investigate Pmt3 modification of S.pombe proteins, we have
found Pmt3-modified species to be present at low levels and
difficult to purify from cell extracts. This makes the task of
identifying novel Pmt3-modified targets in vivo a laborious
process. The S.pombe in vitro Pmt3 modification system will
thus provide a useful and relatively straightforward first step in
the identification of potential Pmt3 targets, which can then be
tested in vivo.
Multiple possible roles have been proposed for SUMO-1
modification. One of these is demonstrated in the case of IκBα,
where SUMO-1 competes with ubiquitin for the same lysine
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residue (12). SUMO-1 modification of IκBα prevents ubiquitin-
ation and hence protects the protein from degradation by
the proteasome. We have no direct evidence that Rad22 is
ubiquitinated or is subject to ubiquitin-dependent proteolysis.
However, Rad22 is somewhat unstable in cell extracts, even in
the presence of the mammalian protease inhibitor cocktail as
can be observed by the doublet of bands in Figures 2 and 3. The
upper band corresponds to the band seen in TCA extracts, with
the lower species likely to be a degradation product. Alterna-
tively Pmt3 modification of Rad22 might affect the location of
Rad22 within cells or within distinct compartments within the
nucleus or might alter its ability to interact with different
proteins.
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